Aegerion Pharma Inc (AEGR) 1.63 $AEGR
Aegerion, QLT Ink Merger Deal to Form Novelion Therapeutics
Zacks Equity Research - Zacks Investment Research - Thu Jun 16, 11:23PM CDT
Aegerion Pharmaceuticals, Inc. (AEGR) announced that it has entered into a definitive merger agreement with QLT Inc. (QLTI).
ABT: 42.13 (+0.24), JNJ: 122.61 (-0.24), QLTI: 1.41 (-0.02), AEGR: 1.63 (-0.04)
Aegerion Pharmaceuticals and QLT Inc. Agree to Strategic Merger
GlobeNewswire - Wed Jun 15, 6:00AM CDT
--Strategic Merger Creates Well-Capitalized, Global Biopharmaceutical Organization with Diverse Portfolio of Two Commercialized Rare Disease Programs and a Phase 3 Ready Ultra-Orphan Development Program Addressing Significant Unmet Medical Need--
QLTI: 1.41 (-0.02), QLT.TO: 1.86 (unch), AEGR: 1.63 (-0.04)
Pre-market Insights on Biotechnology Stocks -- BioMarin Pharma, Alexion Pharma, Aegerion Pharma, and Acorda Therapeutics
PR Newswire - Thu Jun 09, 7:40AM CDT
On Wednesday, June 08, 2016, the NASDAQ Composite ended the trading session at 4,974.64, up 0.26%; the Dow Jones Industrial Average advanced 0.37% to finish at 18,005.05; and the S&P 500 closed at 2,119.12, up 0.33%. The gains were broad based as all the sectors ended the session in positive. ActiveWallSt.com has initiated coverage on the following equities: BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), Alexion Pharmaceuticals Inc. (NASDAQ: ALXN), Aegerion Pharmaceuticals Inc. (NASDAQ: AEGR), and Acorda Therapeutics Inc. (NASDAQ: ACOR). Learn more about these stocks by accessing their free trade alerts at:
BMRN: 89.65 (-1.84), ALXN: 124.55 (+0.13), AEGR: 1.63 (-0.04), ACOR: 26.03 (-0.18)
Aegerion Pharmaceuticals Grants Stock Options Under Inducement Program
GlobeNewswire - Tue Jun 07, 3:45PM CDT
Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases, today announced that on June 1, 2016, Aegerion granted stock options to purchase an aggregate of 10,958 shares of common stock to six new employees under the inducement stock option program described below. Each stock option has an exercise price per share equal to $1.93, the closing price of Aegerion's common stock on the grant date; vests 25% on the first anniversary of the date of grant with the remaining 75% to vest in monthly installments over the three years thereafter; has a ten year term; and is subject to the terms and conditions of Aegerion's Inducement Award Stock Option Plan, and the terms and conditions of a stock option agreement covering the grant.
AEGR: 1.63 (-0.04)
Robbins Arroyo LLP Is Investigating the Officers and Directors of Aegerion Pharmaceuticals, Inc. (AEGR) on Behalf of Shareholders
BusinessWire - Thu May 19, 6:01PM CDT
Shareholder rights law firm Robbins Arroyo LLP is investigating whether certain officers and directors of Aegerion Pharmaceuticals, Inc. (NASDAQGS: AEGR) violated their legal obligations to the company and its shareholders in connection with alleged violations of drug marketing requirements, securities laws, and the Health Insurance Portability and Accountability Act ("HIPAA"
. Aegerion, a biopharmaceutical company, develops and commercializes therapies for patients with debilitating rare diseases in the United States.
AEGR: 1.63 (-0.04)
Aegerion (AEGR) Misses Q1 Earnings Estimates, Cuts View
Zacks Equity Research - Zacks Investment Research - Tue May 17, 9:06AM CDT
Aegerion Pharmaceuticals, Inc. (AEGR) reported a loss of $1.85 per share in the first quarter of 2016, much wider than both the Zacks Consensus Estimate of a loss of 54 cents.
ABT: 42.13 (+0.24), JNJ: 122.61 (-0.24), PFE: 36.08 (-0.04), AEGR: 1.63 (-0.04)
Aegerion reports 1Q loss
Automated Insights - Mon May 16, 3:19PM CDT
CAMBRIDGE, Mass. (AP) _ Aegerion Pharmaceuticals Inc. (AEGR) on Monday reported a loss of $65.6 million in its first quarter.
AEGR: 1.63 (-0.04)
Aegerion Pharmaceuticals Announces First Quarter 2016 Financial Results
GlobeNewswire - Mon May 16, 3:05PM CDT
-- Company records $35.7 million in total net product sales
AEGR: 1.63 (-0.04)
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces the Commencement of an Investigation into Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Aegerion, Inc.
BusinessWire - Fri May 13, 2:41PM CDT
Levi & Korsinsky announces it has commenced an investigation of Aegerion, Inc. ("Aegerion" or the "Company" (NASDAQ:AEGR) concerning possible breaches of fiduciary duty.
AEGR: 1.63 (-0.04)
Faruqi & Faruqi, LLP is Investigating Aegerion Pharmaceuticals, Inc. (AEGR) on Behalf of its Shareholders
PR Newswire - Fri May 13, 12:52PM CDT
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential misconduct at Aegerion Pharmaceuticals, Inc. ("Aegerion" or the "Company" (NASDAQ:AEGR).
AEGR: 1.63 (-0.04)
Bernstein Liebhard LLP Investigates Claims On Behalf Of Those Who Hold Aegerion Pharmaceuticals, Inc. Stock
PR Newswire - Fri May 13, 11:43AM CDT
Bernstein Liebhard LLP is investigating whether the Board of Directors of Aegerion Pharmaceuticals, Inc. ("Aegerion" or the "Company" (NASDAQ: AEGR) breached their fiduciary duties to shareholders by violating the Food, Drug, and Cosmetic Act (the "Act" in connection with the Company's sales activities and disclosures related to its lead drug, JUXTAPID.
AEGR: 1.63 (-0.04)
Aegerion Enters into Settlement Agreement with DoJ and SEC
Zacks Equity Research - Zacks Investment Research - Fri May 13, 8:36AM CDT
Aegerion Pharmaceuticals, Inc. (AEGR) announced that it has reached preliminary agreements with the U.S. DoJ and staff of the SEC.
ABT: 42.13 (+0.24), AEGR: 1.63 (-0.04), ACOR: 26.03 (-0.18), SNY: 41.08 (+0.23)
Aegerion Pharmaceuticals Announces Preliminary Agreements in Principle With DOJ and SEC Related to Ongoing Investigations
GlobeNewswire - Thu May 12, 7:15AM CDT
Aegerion Pharmaceuticals, Inc. ("Aegerion" or the "Company" (NASDAQ:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases, announced today that it has reached preliminary agreements in principle with the Department of Justice ( "DOJ" and the staff of the Securities and Exchange Commission ("SEC" regarding a settlement of the ongoing investigations by these agencies into the Company's sales activities and disclosures related to JUXTAPID(R) (lomitapide) capsules ("JUXTAPID".
AEGR: 1.63 (-0.04)
Aegerion Pharmaceuticals to Announce First Quarter 2016 Financial Results on Monday, May 16
GlobeNewswire - Wed May 11, 7:05AM CDT
Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases, announced that the Company will host a conference call and live audio webcast at 5:00 p.m. EDT on Monday, May 16, 2016, to provide a business update and to discuss its first quarter 2016 financial and operating results.
AEGR: 1.63 (-0.04)
SurModics (SRDX) Beats Q2 Earnings & Revenues Estimates
Zacks Equity Research - Zacks Investment Research - Tue May 03, 12:27PM CDT
SurModics' (SRDX) second-quarter of fiscal 2016 adjusted earnings of 20 cents per share beat the Zacks Consensus Estimate of 8 cents.
SRDX: 24.61 (-0.05), GILD: 86.22 (-0.33), ANIP: 56.15 (-0.36), AEGR: 1.63 (-0.04)
Mallinckrodt (MNK) Tops Q2 Earnings and Sales, Ups View
Zacks Equity Research - Zacks Investment Research - Tue May 03, 9:49AM CDT
Mallinckrodt (MNK) reported adjusted earnings of $2.01 per share in the second quarter of fiscal 2016 (ended Mar 25, 2016), beating the Zacks Consensus Estimate of $1.72.
MNK: 62.54 (+0.25), GILD: 86.22 (-0.33), MDCO: 35.82 (+0.92), AEGR: 1.63 (-0.04)
Merrimack (MACK) Posts Narrower-than-Expected Loss in Q1
Zacks Equity Research - Zacks Investment Research - Tue May 03, 9:33AM CDT
Merrimack Pharmaceuticals, Inc. (MACK) reported a loss of 33 cents per share in the first quarter of 2016, narrower than both the Zacks Consensus Estimate of 39 cents and the prior-quarter loss of 41 cents.
MACK: 5.67 (+0.05), GILD: 86.22 (-0.33), AEGR: 1.63 (-0.04), BXLT: 46.02 (-0.18)
Mylan Beats on Q1 Earnings, Revenues Lag, 2016 View Intact
Zacks Equity Research - Zacks Investment Research - Tue May 03, 8:30AM CDT
Mylan's (MYL) first-quarter 2016 earnings (excluding special items) of 76 cents per share beat the Zacks Consensus Estimate by a penny.
GILD: 86.22 (-0.33), ANIP: 56.15 (-0.36), MYL: 44.60 (+0.06), AEGR: 1.63 (-0.04)
Aerie (AERI) Q1 Loss Wider than Expected, Pipeline in Focus
Zacks Equity Research - Zacks Investment Research - Tue May 03, 7:57AM CDT
Aerie Pharmaceuticals, Inc. (AERI) posted a first-quarter 2016 loss of 85 cents per share, wider than both the Zacks Consensus Estimate of a loss of 66 cents and the year-ago loss of 70 cents.
GILD: 86.22 (-0.33), SHPG: 187.54 (-0.67), AERI: 17.97 (+0.36), AEGR: 1.63 (-0.04)
Aegerion, QLT Ink Merger Deal to Form Novelion Therapeutics
Zacks Equity Research - Zacks Investment Research - Thu Jun 16, 11:23PM CDT
Aegerion Pharmaceuticals, Inc. (AEGR) announced that it has entered into a definitive merger agreement with QLT Inc. (QLTI).
ABT: 42.13 (+0.24), JNJ: 122.61 (-0.24), QLTI: 1.41 (-0.02), AEGR: 1.63 (-0.04)
Aegerion Pharmaceuticals and QLT Inc. Agree to Strategic Merger
GlobeNewswire - Wed Jun 15, 6:00AM CDT
--Strategic Merger Creates Well-Capitalized, Global Biopharmaceutical Organization with Diverse Portfolio of Two Commercialized Rare Disease Programs and a Phase 3 Ready Ultra-Orphan Development Program Addressing Significant Unmet Medical Need--
QLTI: 1.41 (-0.02), QLT.TO: 1.86 (unch), AEGR: 1.63 (-0.04)
Pre-market Insights on Biotechnology Stocks -- BioMarin Pharma, Alexion Pharma, Aegerion Pharma, and Acorda Therapeutics
PR Newswire - Thu Jun 09, 7:40AM CDT
On Wednesday, June 08, 2016, the NASDAQ Composite ended the trading session at 4,974.64, up 0.26%; the Dow Jones Industrial Average advanced 0.37% to finish at 18,005.05; and the S&P 500 closed at 2,119.12, up 0.33%. The gains were broad based as all the sectors ended the session in positive. ActiveWallSt.com has initiated coverage on the following equities: BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), Alexion Pharmaceuticals Inc. (NASDAQ: ALXN), Aegerion Pharmaceuticals Inc. (NASDAQ: AEGR), and Acorda Therapeutics Inc. (NASDAQ: ACOR). Learn more about these stocks by accessing their free trade alerts at:
BMRN: 89.65 (-1.84), ALXN: 124.55 (+0.13), AEGR: 1.63 (-0.04), ACOR: 26.03 (-0.18)
Aegerion Pharmaceuticals Grants Stock Options Under Inducement Program
GlobeNewswire - Tue Jun 07, 3:45PM CDT
Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases, today announced that on June 1, 2016, Aegerion granted stock options to purchase an aggregate of 10,958 shares of common stock to six new employees under the inducement stock option program described below. Each stock option has an exercise price per share equal to $1.93, the closing price of Aegerion's common stock on the grant date; vests 25% on the first anniversary of the date of grant with the remaining 75% to vest in monthly installments over the three years thereafter; has a ten year term; and is subject to the terms and conditions of Aegerion's Inducement Award Stock Option Plan, and the terms and conditions of a stock option agreement covering the grant.
AEGR: 1.63 (-0.04)
Robbins Arroyo LLP Is Investigating the Officers and Directors of Aegerion Pharmaceuticals, Inc. (AEGR) on Behalf of Shareholders
BusinessWire - Thu May 19, 6:01PM CDT
Shareholder rights law firm Robbins Arroyo LLP is investigating whether certain officers and directors of Aegerion Pharmaceuticals, Inc. (NASDAQGS: AEGR) violated their legal obligations to the company and its shareholders in connection with alleged violations of drug marketing requirements, securities laws, and the Health Insurance Portability and Accountability Act ("HIPAA"
. Aegerion, a biopharmaceutical company, develops and commercializes therapies for patients with debilitating rare diseases in the United States. AEGR: 1.63 (-0.04)
Aegerion (AEGR) Misses Q1 Earnings Estimates, Cuts View
Zacks Equity Research - Zacks Investment Research - Tue May 17, 9:06AM CDT
Aegerion Pharmaceuticals, Inc. (AEGR) reported a loss of $1.85 per share in the first quarter of 2016, much wider than both the Zacks Consensus Estimate of a loss of 54 cents.
ABT: 42.13 (+0.24), JNJ: 122.61 (-0.24), PFE: 36.08 (-0.04), AEGR: 1.63 (-0.04)
Aegerion reports 1Q loss
Automated Insights - Mon May 16, 3:19PM CDT
CAMBRIDGE, Mass. (AP) _ Aegerion Pharmaceuticals Inc. (AEGR) on Monday reported a loss of $65.6 million in its first quarter.
AEGR: 1.63 (-0.04)
Aegerion Pharmaceuticals Announces First Quarter 2016 Financial Results
GlobeNewswire - Mon May 16, 3:05PM CDT
-- Company records $35.7 million in total net product sales
AEGR: 1.63 (-0.04)
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces the Commencement of an Investigation into Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Aegerion, Inc.
BusinessWire - Fri May 13, 2:41PM CDT
Levi & Korsinsky announces it has commenced an investigation of Aegerion, Inc. ("Aegerion" or the "Company"
(NASDAQ:AEGR) concerning possible breaches of fiduciary duty. AEGR: 1.63 (-0.04)
Faruqi & Faruqi, LLP is Investigating Aegerion Pharmaceuticals, Inc. (AEGR) on Behalf of its Shareholders
PR Newswire - Fri May 13, 12:52PM CDT
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential misconduct at Aegerion Pharmaceuticals, Inc. ("Aegerion" or the "Company"
(NASDAQ:AEGR). AEGR: 1.63 (-0.04)
Bernstein Liebhard LLP Investigates Claims On Behalf Of Those Who Hold Aegerion Pharmaceuticals, Inc. Stock
PR Newswire - Fri May 13, 11:43AM CDT
Bernstein Liebhard LLP is investigating whether the Board of Directors of Aegerion Pharmaceuticals, Inc. ("Aegerion" or the "Company"
(NASDAQ: AEGR) breached their fiduciary duties to shareholders by violating the Food, Drug, and Cosmetic Act (the "Act" in connection with the Company's sales activities and disclosures related to its lead drug, JUXTAPID. AEGR: 1.63 (-0.04)
Aegerion Enters into Settlement Agreement with DoJ and SEC
Zacks Equity Research - Zacks Investment Research - Fri May 13, 8:36AM CDT
Aegerion Pharmaceuticals, Inc. (AEGR) announced that it has reached preliminary agreements with the U.S. DoJ and staff of the SEC.
ABT: 42.13 (+0.24), AEGR: 1.63 (-0.04), ACOR: 26.03 (-0.18), SNY: 41.08 (+0.23)
Aegerion Pharmaceuticals Announces Preliminary Agreements in Principle With DOJ and SEC Related to Ongoing Investigations
GlobeNewswire - Thu May 12, 7:15AM CDT
Aegerion Pharmaceuticals, Inc. ("Aegerion" or the "Company"
(NASDAQ:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases, announced today that it has reached preliminary agreements in principle with the Department of Justice ( "DOJ" and the staff of the Securities and Exchange Commission ("SEC" regarding a settlement of the ongoing investigations by these agencies into the Company's sales activities and disclosures related to JUXTAPID(R) (lomitapide) capsules ("JUXTAPID". AEGR: 1.63 (-0.04)
Aegerion Pharmaceuticals to Announce First Quarter 2016 Financial Results on Monday, May 16
GlobeNewswire - Wed May 11, 7:05AM CDT
Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases, announced that the Company will host a conference call and live audio webcast at 5:00 p.m. EDT on Monday, May 16, 2016, to provide a business update and to discuss its first quarter 2016 financial and operating results.
AEGR: 1.63 (-0.04)
SurModics (SRDX) Beats Q2 Earnings & Revenues Estimates
Zacks Equity Research - Zacks Investment Research - Tue May 03, 12:27PM CDT
SurModics' (SRDX) second-quarter of fiscal 2016 adjusted earnings of 20 cents per share beat the Zacks Consensus Estimate of 8 cents.
SRDX: 24.61 (-0.05), GILD: 86.22 (-0.33), ANIP: 56.15 (-0.36), AEGR: 1.63 (-0.04)
Mallinckrodt (MNK) Tops Q2 Earnings and Sales, Ups View
Zacks Equity Research - Zacks Investment Research - Tue May 03, 9:49AM CDT
Mallinckrodt (MNK) reported adjusted earnings of $2.01 per share in the second quarter of fiscal 2016 (ended Mar 25, 2016), beating the Zacks Consensus Estimate of $1.72.
MNK: 62.54 (+0.25), GILD: 86.22 (-0.33), MDCO: 35.82 (+0.92), AEGR: 1.63 (-0.04)
Merrimack (MACK) Posts Narrower-than-Expected Loss in Q1
Zacks Equity Research - Zacks Investment Research - Tue May 03, 9:33AM CDT
Merrimack Pharmaceuticals, Inc. (MACK) reported a loss of 33 cents per share in the first quarter of 2016, narrower than both the Zacks Consensus Estimate of 39 cents and the prior-quarter loss of 41 cents.
MACK: 5.67 (+0.05), GILD: 86.22 (-0.33), AEGR: 1.63 (-0.04), BXLT: 46.02 (-0.18)
Mylan Beats on Q1 Earnings, Revenues Lag, 2016 View Intact
Zacks Equity Research - Zacks Investment Research - Tue May 03, 8:30AM CDT
Mylan's (MYL) first-quarter 2016 earnings (excluding special items) of 76 cents per share beat the Zacks Consensus Estimate by a penny.
GILD: 86.22 (-0.33), ANIP: 56.15 (-0.36), MYL: 44.60 (+0.06), AEGR: 1.63 (-0.04)
Aerie (AERI) Q1 Loss Wider than Expected, Pipeline in Focus
Zacks Equity Research - Zacks Investment Research - Tue May 03, 7:57AM CDT
Aerie Pharmaceuticals, Inc. (AERI) posted a first-quarter 2016 loss of 85 cents per share, wider than both the Zacks Consensus Estimate of a loss of 66 cents and the year-ago loss of 70 cents.
GILD: 86.22 (-0.33), SHPG: 187.54 (-0.67), AERI: 17.97 (+0.36), AEGR: 1.63 (-0.04)
